Sensus Healthcare (NASDAQ:SRTS - Get Free Report) is set to post its quarterly earnings results after the market closes on Thursday, November 14th. Analysts expect Sensus Healthcare to post earnings of ($0.02) per share for the quarter. Individual that wish to register for the company's earnings conference call can do so using this link.
Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.07. Sensus Healthcare had a return on equity of 13.46% and a net margin of 18.27%. The company had revenue of $9.24 million for the quarter, compared to analysts' expectations of $7.00 million. During the same quarter in the prior year, the firm earned ($0.02) earnings per share. On average, analysts expect Sensus Healthcare to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Sensus Healthcare Stock Down 2.2 %
NASDAQ:SRTS traded down $0.15 during midday trading on Thursday, hitting $6.54. The stock had a trading volume of 121,695 shares, compared to its average volume of 273,499. Sensus Healthcare has a one year low of $1.79 and a one year high of $7.18. The company has a market capitalization of $107.19 million, a price-to-earnings ratio of 15.95 and a beta of 1.04. The stock has a 50-day moving average of $6.26 and a 200 day moving average of $5.78.
Analyst Ratings Changes
SRTS has been the topic of several research analyst reports. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Sensus Healthcare in a research note on Monday, August 12th. Roth Capital raised Sensus Healthcare to a "strong-buy" rating in a research report on Friday, July 12th.
Read Our Latest Research Report on Sensus Healthcare
About Sensus Healthcare
(
Get Free Report)
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Further Reading
Before you consider Sensus Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sensus Healthcare wasn't on the list.
While Sensus Healthcare currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
